Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination

View Full Paper
Ask AI
Bookmark
Share

Authors

SOShane W. O’BrienMMMichael T. McCabe

Discussion

Loading...

Member takes

Overview

Combination therapy shows enhanced cytotoxic response and prolonged survival in acute myeloid leukemia, indicating a promising treatment strategy.

Key Points

  • Momelotinib with venetoclax and azacitidine improves outcomes in acute myeloid leukemia.
  • The combination resulted in superior cytotoxic response in FLT3 wild-type and mutant AML cells.
  • Observational analysis in PDX mouse models highlighted prolonged survival and enhanced leukemic clearance.
  • The findings suggest that targeting multiple resistance mechanisms may be crucial for effective AML treatment.

Cite This Study

O’Brien et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc2bhttps://doi.org/10.1182/blood-2025-7850
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML2025
  2. 2Momelotinib-mediated transcriptional reprogramming induces synthetic lethal interaction with calcineurin-NFAT signaling2025
  3. 3Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes2025
  4. 4Combined FLT3 and EZH1/2 inhibition reduces LSCs and promotes myeloid differentiation in PDX models of AML2025
  5. 5Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis2025